Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Hematopoietic recovery post-CAR-T

Jordan Gauthier • 30 Mar 2020
General

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines hematopoietic recovery post-CAR T-cell therapy, highlighting the significance of slow count recovery after the use of CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jordan Gauthier

Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
3:40
Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier • 28 Jan 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
IACH webinar: continuing the CAR-T discussion amid COVID-19
1:46
IACH webinar: continuing the CAR-T discussion amid COVID-19
Jordan Gauthier • 30 Mar 2020
CLL outcomes after CD19 CAR-T with ibrutinib
3:50
CLL outcomes after CD19 CAR-T with ibrutinib
Jordan Gauthier • 30 Mar 2020

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals